Retatrutide and tirzepatide are next-generation metabolic research peptides. Tirzepatide is a dual GLP-1 + GIP agonist; retatrutide goes further as a triple agonist — adding the glucagon receptor. That extra target is the central research distinction.
What Is Tirzepatide?
Tirzepatide is a dual incretin receptor agonist targeting both GLP-1 and GIP receptors. In research settings it is studied for combined effects on insulin secretion, glucagon suppression, and appetite signaling in metabolic disease models.
Tirzepatide At a Glance
- Dual GLP-1 + GIP receptor agonist
- Targets two incretin pathways
- Studied for combined metabolic effects
- Researched in obesity and type-2 diabetes models
What Is Retatrutide?
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors — an investigational peptide designed to engage three metabolic pathways at once. In research settings it is studied for the added glucagon-receptor effects on energy expenditure and hepatic lipid metabolism in animal models.
Retatrutide At a Glance
- Triple GLP-1 + GIP + glucagon receptor agonist
- Targets three metabolic pathways
- Studied for energy expenditure and hepatic effects
- Researched in obesity and metabolic syndrome models
Mechanism of Action in Research
The defining difference is the glucagon receptor:
- Tirzepatide — dual agonist (GLP-1 + GIP); no glucagon receptor activity
- Retatrutide — triple agonist (GLP-1 + GIP + glucagon); adds glucagon pathway
- Glucagon agonism in retatrutide is studied for increased energy expenditure
- GIP co-agonism in both is studied for adipose and insulin-sensitizing effects
"Triple incretin/glucagon agonism extends the dual-agonist concept by adding a glucagon-receptor component studied for energy expenditure and hepatic metabolic effects."
Key Differences
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Mechanism class | Dual agonist | Triple agonist |
| Glucagon activity | None | Yes (added pathway) |
| Research focus | Incretin metabolic effects | Energy expenditure + hepatic |
| Pathway breadth | 2 receptors | 3 receptors |
Research Applications
In published preclinical research, tirzepatide has been studied in models of insulin sensitivity, glucagon suppression, and appetite regulation. Retatrutide has been studied in models adding glucagon-receptor effects on energy expenditure, hepatic lipid metabolism, and brown adipose tissue activation. Neither research-grade peptide is approved for human use.
Retatrutide's triple agonism adds the glucagon receptor to tirzepatide's dual GLP-1 + GIP base. Researchers studying energy expenditure and hepatic pathways may select retatrutide; those focused on incretin-only effects may select tirzepatide.
Quality Verification
For valid metabolic research, both peptides require documented quality verification:
- Batch-specific Certificate of Analysis (COA)
- HPLC purity verification (typically ≥99%)
- Mass spectrometry identity confirmation
- Cold-chain handling for lyophilized reagents
- Clear 'Research Use Only' labeling
The Bottom Line
Retatrutide and tirzepatide are both multi-receptor metabolic research peptides, but retatrutide's added glucagon agonism makes it mechanistically broader. Both are sold strictly for in vitro laboratory research and have not been evaluated by the FDA for human use.